Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 11,348 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $12.47, for a total transaction of $141,509.56. Following the sale, the insider now owns 21,570 shares of the company’s stock, valued at approximately $268,977.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Cytokinetics, Incorporated (NASDAQ:CYTK) traded down 3.23% on Thursday, hitting $12.00. 735,170 shares of the stock were exchanged. The company’s 50 day moving average price is $13.49 and its 200-day moving average price is $13.02. The company’s market cap is $643.99 million. Cytokinetics, Incorporated has a one year low of $8.51 and a one year high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.03. The company had revenue of $3.05 million for the quarter, compared to the consensus estimate of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Equities research analysts predict that Cytokinetics, Incorporated will post ($2.08) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/10/cytokinetics-incorporated-nasdaqcytk-insider-sells-141509-56-in-stock.html.

Several analysts have recently commented on CYTK shares. BidaskClub upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Cowen and Company reiterated a “buy” rating and issued a $19.00 price objective on shares of Cytokinetics, in a research note on Friday, August 4th. HC Wainwright set a $26.00 price objective on shares of Cytokinetics, and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Monday. Finally, Morgan Stanley started coverage on shares of Cytokinetics, in a research note on Monday, July 31st. They issued an “overweight” rating and a $24.00 price objective for the company. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $21.30.

Large investors have recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new stake in shares of Cytokinetics, during the second quarter worth about $109,000. Municipal Employees Retirement System of Michigan bought a new stake in shares of Cytokinetics, during the second quarter worth about $132,000. LMR Partners LLP bought a new stake in shares of Cytokinetics, during the first quarter worth about $156,000. Bank of America Corp DE boosted its stake in shares of Cytokinetics, by 36.8% in the first quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 3,383 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Cytokinetics, by 4,464.4% in the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 13,036 shares during the last quarter. 59.76% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.